It has come to our notice that certain fraudulent individuals or entities are misusing our Company’s name and TCI’s registered trademarks by promoting and offering regulated and hazardous chemical substances through online platforms like YouTube. We hereby categorically clarify that TCI has no association or connection whatsoever with the products being displayed or sold in the videos. These products have been falsely represented as being associated with TCI, and the unauthorized use of our trademark and brand name is both illegal and misleading. TCI Chemicals markets and sells its products exclusively through its official website and authorized distributors. If you become aware of any such fraudulent activity or require clarification, you may reach out to us at: Sales-IN@TCIchemicals.com. Click Here to View the Caution Notice.
Product Document Searching Made Easy by 2D Code! | [Product Highlights] Endogenous Biotin-Blocking Reagent...Maximum quantity allowed is 999
Non-PEG Linkers for Designing Proteolysis Targeting Chimera Molecules
Proteolysis targeting chimera molecules are bifunctional small molecules which consist of a ubiquitin E3 ligase ligand and a protein of interest (POI) ligand covalently bonded via a linker. The chimera molecules that induce the degradation of POI, while conventional molecules cannot, are regarded as a new drug modality. Although PEG linkers are typically used as linkers, the drug-like structures using non-PEG linkers with shorter linker length have been recently reported.1,2) Non-PEG linkers, 1-Boc-4-(piperidin-4-ylmethyl)piperazine (1) and 1-Boc-4-(piperazin-1-ylmethyl)piperidine (2) can bind to various ligands. The proteolysis targeting chimera molecules derivatized from 1 or 2 are studied as potential oral drugs.
Related Products
Product Category Pages
- Homobifunctional Cross-Linkers
- Heterobifunctional Cross-Linkers
- Proteolysis Targeting Chimera Research Reagents
References
- 1) Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
- 2) Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
